TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

被引：26
|
作者：
Ahn, M. [1 ]
Han, J. [2 ]
Sequist, L. [3 ]
Cho, B. C. [4 ]
Lee, J. S. [5 ]
Kim, S. [6 ]
Su, W. [7 ]
Tsai, C. [8 ]
Yang, J. C. [9 ]
Yu, H. [10 ]
Horn, L. [11 ]
Lee, K. [12 ]
Haddad, V. [13 ]
Frigault, M. [14 ]
Ahmed, G. [13 ]
Yang, L. [15 ]
Ghiorghiu, D. [13 ]
Oxnard, G. [16 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Yonsei Canc Ctr, Med Oncol, Seoul, South Korea
[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[7] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[9] Natl Taiwan Univ Hosp, Taipei, Taiwan
[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[12] Taipei Med Univ, Shuang Ho Hosp, Taipei, Taiwan
[13] Astrazeneca, Cambridge, England
[14] Astrazeneca, Waltham, MA USA
[15] Astrazeneca, Shanghai, Peoples R China
[16] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
non-small cell lung cancer; EGFR-Mutant; MET-amplification;
D O I：
10.1016/j.jtho.2017.09.377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 09.03
引用
收藏
页码：S1768 / S1768
页数：1
相关论文
共 50 条
  • [1] TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
    Han, J-Y.
    Sequist, L. V.
    Ahn, M-J.
    Cho, B. C.
    Yu, H.
    Kim, S-W.
    Yang, J. C-H.
    Lee, J. S.
    Su, W-C.
    Kowalski, D.
    Orlov, S.
    Cantarini, M.
    Verheijen, R. B.
    Mellemgaard, A.
    Frewer, P.
    Ou, X.
    Oxnard, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Sequist, Lecia V.
    Lee, Jong Seok
    Han, Ji-Youn
    Su, Wu-Chou
    Yang, James Chih-Hsin
    Yu, Helena
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Oxnard, Geoffrey
    Cho, Byoung Chul
    CANCER RESEARCH, 2019, 79 (13)
  • [3] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Yu, Helena
    Ahn, Myung-Ju
    Kim, Sang-We
    Cho, Byoung Chul
    Sequist, Lecia
    Orlov, Sergey
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Han, Ji-Youn
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
    Ramalingam, Suresh S.
    Saka, Hideo
    Ahn, Myung-Ju
    Yu, Helena
    Horn, Leora
    Hida, Toyoaki
    Cantarini, Mireille
    Verheijen, Remy
    Wessen, Jonathan
    Oxnard, Geoffrey
    Ohe, Yuichiro
    CANCER RESEARCH, 2019, 79 (13)
  • [5] A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
    Yang, J. -
    Fang, J.
    Shu, Y.
    Chang, J.
    Chen, G.
    He, J.
    Li, W.
    Liu, X.
    Yang, N.
    Zhou, C.
    Huang, J.
    Yang, L.
    Handzel, A.
    Frigault, M.
    Ahmed, G.
    Egile, C.
    Morgan, S.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1769 - S1769
  • [6] The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study
    Hartmaier, Ryan
    Han, Ji-Youn
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Cantarini, Mireille
    Frewer, Paul
    Frigault, Melanie M.
    Oxnard, Geoffrey
    CANCER RESEARCH, 2020, 80 (16)
  • [7] Osimertinib plus Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
    Han, J.
    Sequist, L.
    Ahn, M.
    Cho, B. C.
    Yu, H.
    Kim, S.
    Yang, J. C.
    Lee, J. S.
    Su, W.
    Kowalski, D. M.
    Orlov, S.
    Cantarini, M.
    Ren, S.
    Frewer, P.
    Ou, X.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S227 - S228
  • [8] Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
    Riess, J.
    Kelly, K.
    Schalper, K.
    Shimoda, M.
    Lim, S.
    Monjazeb, A.
    Danenberg, K.
    Moore, E.
    Beckett, L.
    Mack, P.
    Maverakis, E.
    Gandara, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S528 - S528
  • [9] SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
    Ahn, M.
    Cantarini, M.
    Frewer, P.
    Hawkins, G.
    Peters, J.
    Howarth, P.
    Ahmed, G.
    Sahota, T.
    Hartmaier, R.
    Li-Sucholeiki, X.
    Oxnard, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S415 - S416
  • [10] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
12345